-
Je něco špatně v tomto záznamu ?
2-Cl-IB-MECA regulates the proliferative and drug resistance pathways, and facilitates chemosensitivity in pancreatic and liver cancer cell lines
J. Kotulova, K. Lonova, A. Kubickova, J. Vrbkova, P. Kourilova, M. Hajduch, P. Dzubak
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 2006 do Před 1 rokem
Freely Accessible Science Journals
od 2006
ProQuest Central
od 2012-01-01
Medline Complete (EBSCOhost)
od 2013-08-01
Health & Medicine (ProQuest)
od 2012-01-01
PubMed
35039871
DOI
10.3892/ijmm.2022.5086
Knihovny.cz E-zdroje
- MeSH
- adenosin analogy a deriváty MeSH
- buněčné linie MeSH
- léková rezistence MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- nádory jater * farmakoterapie MeSH
- nádory slinivky břišní * genetika MeSH
- proliferace buněk MeSH
- protein Gli1 genetika metabolismus MeSH
- proteiny hedgehog MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Specific A3 adenosine receptor (A3AR) agonist, 2-chloro-N6-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine (2-Cl-IB-MECA), demonstrates anti-proliferative effects on various types of tumor. In the present study, the cytotoxicity of 2-Cl-IB-MECA was analyzed in a panel of tumor and non-tumor cell lines and its anticancer mechanisms in JoPaca-1 pancreatic and Hep-3B hepatocellular carcinoma cell lines were also investigated. Initially, decreased tumor cell proliferation, cell accumulation in the G1 phase and inhibition of DNA and RNA synthesis was found. Furthermore, western blot analysis showed decreased protein expression level of β-catenin, patched1 (Ptch1) and glioma-associated oncogene homolog zinc finger protein 1 (Gli1), which are components of the Wnt/β-catenin and Sonic hedgehog/Ptch/Gli transduction pathways. In concordance with these findings, the protein expression levels of cyclin D1 and c-Myc were reduced. Using a luciferase assay, it was revealed for the first time a decrease in β-catenin transcriptional activity, as an early event following 2-Cl-IB-MECA treatment. In addition, the protein expression levels of multidrug resistance-associated protein 1 and P-glycoprotein (P-gp) were reduced and the P-gp xenobiotic efflux function was also reduced. Next, the enhancing effects of 2-Cl-IB-MECA on the cytotoxicity of conventional chemotherapy was investigated. It was found that 2-Cl-IB-MECA enhanced carboplatin and doxorubicin cytotoxic effects in the JoPaca-1 and Hep-3B cell lines, and a greater synergy was found in the highly tumorigenic JoPaca-1 cell line. This provides a novel in vitro rationale for the utilization of 2-Cl-IB-MECA in combination with chemotherapeutic agents, not only for hepatocellular carcinoma, but also for pancreatic cancer. Other currently used conventional chemotherapeutics, fluorouracil and gemcitabine, showed synergy only when combined with high doses of 2-Cl-IB-MECA. Notably, experiments with A3AR-specific antagonist, N-[9-Chloro-2-(2-furanyl)(1,2,4)-triazolo(1,5-c)quinazolin-5-yl]benzene acetamide, revealed that 2-Cl-IB-MECA had antitumor effects via both A3AR-dependent and -independent pathways. In conclusion, the present study identified novel antitumor mechanisms of 2-Cl-IB-MECA in pancreatic and hepatocellular carcinoma in vitro that further underscores the importance of A3AR agonists in cancer therapy.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22019289
- 003
- CZ-PrNML
- 005
- 20220804135519.0
- 007
- ta
- 008
- 220720s2022 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3892/ijmm.2022.5086 $2 doi
- 035 __
- $a (PubMed)35039871
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Kotulova, Jana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic
- 245 10
- $a 2-Cl-IB-MECA regulates the proliferative and drug resistance pathways, and facilitates chemosensitivity in pancreatic and liver cancer cell lines / $c J. Kotulova, K. Lonova, A. Kubickova, J. Vrbkova, P. Kourilova, M. Hajduch, P. Dzubak
- 520 9_
- $a Specific A3 adenosine receptor (A3AR) agonist, 2-chloro-N6-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine (2-Cl-IB-MECA), demonstrates anti-proliferative effects on various types of tumor. In the present study, the cytotoxicity of 2-Cl-IB-MECA was analyzed in a panel of tumor and non-tumor cell lines and its anticancer mechanisms in JoPaca-1 pancreatic and Hep-3B hepatocellular carcinoma cell lines were also investigated. Initially, decreased tumor cell proliferation, cell accumulation in the G1 phase and inhibition of DNA and RNA synthesis was found. Furthermore, western blot analysis showed decreased protein expression level of β-catenin, patched1 (Ptch1) and glioma-associated oncogene homolog zinc finger protein 1 (Gli1), which are components of the Wnt/β-catenin and Sonic hedgehog/Ptch/Gli transduction pathways. In concordance with these findings, the protein expression levels of cyclin D1 and c-Myc were reduced. Using a luciferase assay, it was revealed for the first time a decrease in β-catenin transcriptional activity, as an early event following 2-Cl-IB-MECA treatment. In addition, the protein expression levels of multidrug resistance-associated protein 1 and P-glycoprotein (P-gp) were reduced and the P-gp xenobiotic efflux function was also reduced. Next, the enhancing effects of 2-Cl-IB-MECA on the cytotoxicity of conventional chemotherapy was investigated. It was found that 2-Cl-IB-MECA enhanced carboplatin and doxorubicin cytotoxic effects in the JoPaca-1 and Hep-3B cell lines, and a greater synergy was found in the highly tumorigenic JoPaca-1 cell line. This provides a novel in vitro rationale for the utilization of 2-Cl-IB-MECA in combination with chemotherapeutic agents, not only for hepatocellular carcinoma, but also for pancreatic cancer. Other currently used conventional chemotherapeutics, fluorouracil and gemcitabine, showed synergy only when combined with high doses of 2-Cl-IB-MECA. Notably, experiments with A3AR-specific antagonist, N-[9-Chloro-2-(2-furanyl)(1,2,4)-triazolo(1,5-c)quinazolin-5-yl]benzene acetamide, revealed that 2-Cl-IB-MECA had antitumor effects via both A3AR-dependent and -independent pathways. In conclusion, the present study identified novel antitumor mechanisms of 2-Cl-IB-MECA in pancreatic and hepatocellular carcinoma in vitro that further underscores the importance of A3AR agonists in cancer therapy.
- 650 _2
- $a adenosin $x analogy a deriváty $7 D000241
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a proliferace buněk $7 D049109
- 650 _2
- $a léková rezistence $7 D004351
- 650 _2
- $a proteiny hedgehog $7 D053823
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory jater $x farmakoterapie $7 D008113
- 650 12
- $a nádory slinivky břišní $x genetika $7 D010190
- 650 _2
- $a protein Gli1 $x genetika $x metabolismus $7 D000071676
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Lonova, Katerina $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic
- 700 1_
- $a Kubickova, Agata $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic
- 700 1_
- $a Vrbkova, Jana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic
- 700 1_
- $a Kourilova, Pavla $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic
- 700 1_
- $a Hajduch, Marian $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic
- 700 1_
- $a Dzubak, Petr $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic
- 773 0_
- $w MED00173213 $t International journal of molecular medicine $x 1791-244X $g Roč. 49, č. 3 (2022)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35039871 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804135513 $b ABA008
- 999 __
- $a ok $b bmc $g 1822756 $s 1170532
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 49 $c 3 $e 20220118 $i 1791-244X $m International Journal of Molecular Medicine $n Int. J. Mol. Med. $x MED00173213
- LZP __
- $a Pubmed-20220720